Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patientKing of...
Melanoma
Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while...
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance
Agreement covers contract development and manufacturing of lead compound PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio...
Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT
Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development programHOUSTON, July 23, 2025 (GLOBE NEWSWIRE)...
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that...
Sona Announces Canadian Melanoma Clinical ‘Pilot’ Study Ethics Approval
Halifax, Nova Scotia--(Newsfile Corp. - July 23, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an...
ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia
ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia Following the FDA ODD, European designation...
Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025
Executive Chairman & CEO of the Company to Participate in a Fireside ChatPhiladelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) -...
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia Clinical data showing unprecedented remission rates in...
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture...
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area...
OncoHost Named Gold Winner in 2025 Merit Awards for Business in Research & Development
BINYAMINA, Israel and CARY, N.C., July 9, 2025 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine...
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term...
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
Substantial clinical need expected to facilitate rapid overall trial enrollmentHOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:...
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer,...
First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy
Trial is expected to provide key insights on safety, tolerability and immune system response for its THT treatment of late-stage...
Sona Announces Ethics Committee Approval For Melanoma Clinical Trial
Halifax, Nova Scotia--(Newsfile Corp. - June 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an...
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated...
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in...